• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Considerations for sustainable influenza vaccine production in developing countries

tetano

Editor, Senior Moderator
Vaccine. 2016 Sep 7. pii: S0264-410X(16)30743-5. doi: 10.1016/j.vaccine.2016.08.056. [Epub ahead of print]
[h=1]Considerations for sustainable influenza vaccine production in developing countries.[/h] Nannei C[SUP]1[/SUP], Chadwick C[SUP]2[/SUP], Fatima H[SUP]3[/SUP], Goldin S[SUP]4[/SUP], Grubo M[SUP]5[/SUP], Ganim A[SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Through its Global Action Plan for Influenza Vaccines (GAP), the World Health Organization (WHO) in collaboration with the United States Department of Health and Human Services has produced a checklist to support policy-makers and influenza vaccine manufacturers in identifying key technological, political, financial, and logistical issues affecting the sustainability of influenza vaccine production. This checklist highlights actions in five key areas that are beneficial for establishing successful local vaccine manufacturing. These five areas comprise: (1) the policy environment and health-care systems; (2) surveillance systems and influenza evidence; (3) product development and manufacturing; (4) product approval and regulation; and (5) communication to support influenza vaccination. Incorporating the checklist into national vaccine production programmes has identified the policy gaps and next steps for countries involved in GAP's Technology Transfer Initiative. Lessons learnt from country experiences provide context and insight that complement the checklist's goal of simplifying the complexities of influenza prevention, preparedness, and vaccine manufacturing.
Copyright ? 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.


[h=4]KEYWORDS:[/h] Pandemic influenza preparedness; Policy coherence; Sustainability; Vaccine manufacturing

PMID: 27614783 DOI: 10.1016/j.vaccine.2016.08.056
[PubMed - as supplied by publisher] Free full text
 
Back
Top Bottom